Posted by Michael Wonder on 06 Mar 2023
Will reimbursement criteria of SMA treatment Spinraza change?
6 March 2023 - The discussion will likely begin in earnest this month to expand reimbursement criteria for Spinraza (nusinersen sodium), Biogen’s treatment for spinal muscular atrophy.
Accordingly, market watchers pay attention to whether the authorities will put Roche’s oral treatment, Evysdi (risdiplam), on the reimbursement list, which has been shelved due to the review of Spinraza’s reimbursement criteria.
